Keall, P. J. et al. Integrated MRI-guided radiotherapy—opportunities and challenges. Nat. Rev. Clin. Oncol. 19, 458–470 (2022).
Jaffray, D. A. Image-guided radiotherapy: from current concept to future perspectives. Nat. Rev. Clin. Oncol. 9, 688–699 (2012).
Bernstein, M. B., Krishnan, S., Hodge, J. W. & Chang, J. Y. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat. Rev. Clin. Oncol. 13, 516–524 (2016).
Senthi, S., Lagerwaard, F. J., Haasbeek, C. J. A., Slotman, B. J. & Senan, S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 13, 802–809 (2012).
Feng, M. et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. JAMA Oncol. 4, 40–47 (2018).
Sogono, P. et al. Safety, efficacy, and patterns of failure after single-fraction stereotactic body radiation therapy (SBRT) for oligometastases. Int. J. Radiat. Oncol. Biol. Phys. 109, 756–763 (2021).
Hörner-Rieber, J. et al. Long-term follow-up and patterns of recurrence of patients with oligometastatic NSCLC treated with pulmonary SBRT. Clin Lung Cancer 20, e667–e677 (2019).
Ali, M. et al. The role of stereotactic ablative body radiotherapy in renal cell carcinoma. Eur. Urol. 82, 613–622 (2022).
Weichselbaum, R. R., Liang, H., Deng, L. & Fu, Y.-X. Radiotherapy and immunotherapy: a beneficial liaison? Nat. Rev. Clin. Oncol. 14, 365–379 (2017).
Siva, S. et al. Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: the RAPPORT trial. J. Clin. Oncol. 39, 277 (2021).
McBride, S. et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J. Clin. Oncol. 39, 30–37 (2020).
Hall, W. A. et al. NRG-GU012: randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI). J. Clin. Oncol. 41, TPS4604 (2023).
Katipally, R. R., Pitroda, S. P., Juloori, A., Chmura, S. J. & Weichselbaum, R. R. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat. Rev. Clin. Oncol. 19, 585–599 (2022).
Chen, H., Zhang, W., Zhu, G., Xie, J. & Chen, X. Rethinking cancer nanotheranostics. Nat. Rev. Mater. 2, 17024 (2017).
Her, S., Jaffray, D. A. & Allen, C. Gold nanoparticles for applications in cancer radiotherapy: mechanisms and recent advancements. Adv. Drug Deliv. Rev. 109, 84–101 (2017).
Lu, K. et al. Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy. Nat. Biomed. Eng. 2, 600–610 (2018).
Ni, K. et al. Synergistic checkpoint-blockade and radiotherapy–radiodynamic therapy via an immunomodulatory nanoscale metal–organic framework. Nat. Biomed. Eng. 6, 144–156 (2022).
Bonvalot, S. et al. First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas. Clin. Cancer Res. 23, 908–917 (2017).
NBTXR3 crystalline nanoparticles and radiation therapy in treating randomized patients in two arms with soft tissue sarcoma of the extremity and trunk wall. https://clinicaltrials.gov/study/NCT02379845
Detappe, A. et al. Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy. J. Control. Release 238, 103–113 (2016).
Lux, F. et al. AGuIX® from bench to bedside—transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. Br. J. Radiol. 92, 20180365 (2018).
Radiosensitization of multiple brain metastases using AGuIX gadolinium based nanoparticles (NANO-RAD). https://clinicaltrials.gov/study/NCT02820454
Cui, L. et al. Radiosensitization by gold nanoparticles: will they ever make it to the clinic? Radiother. Oncol. 124, 344–356 (2017).
Moloudi, K. et al. Critical parameters to translate gold nanoparticles as radiosensitizing agents into the clinic. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 15, e1886 (2023).
Loynachan, C. N. et al. Renal clearable catalytic gold nanoclusters for in vivo disease monitoring. Nat. Nanotechnol. 14, 883–890 (2019).
Jiang, X., Du, B. & Zheng, J. Glutathione-mediated biotransformation in the liver modulates nanoparticle transport. Nat. Nanotechnol. 14, 874–882 (2019).
Huang, Y., Yu, M. & Zheng, J. Proximal tubules eliminate endocytosed gold nanoparticles through an organelle-extrusion-mediated self-renewal mechanism. Nat. Nanotechnol. 18, 637–646 (2023).
Du, B. et al. Glomerular barrier behaves as an atomically precise bandpass filter in a sub-nanometre regime. Nat. Nanotechnol. 12, 1096–1102 (2017).
Schwartz-Duval, A. S. et al. Intratumoral biosynthesis of gold nanoclusters by pancreatic cancer to overcome delivery barriers to radiosensitization. ACS Nano 18, 1865–1881 (2024).
Luo, D. et al. Targeted gold nanocluster-enhanced radiotherapy of prostate cancer. Small 15, 1900968 (2019).
Jia, T.-T. et al. Atomically precise gold–levonorgestrel nanocluster as a radiosensitizer for enhanced cancer therapy. ACS Nano 13, 8320–8328 (2019).
Broekgaarden, M. et al. Surface functionalization of gold nanoclusters with arginine: a trade-off between microtumor uptake and radiotherapy enhancement. Nanoscale 12, 6959–6963 (2020).
Astorgues-Xerri, L. et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat. Rev. 40, 307–319 (2014).
Wu, R. et al. Prognostic significance of galectin-1 expression in patients with cancer: a meta-analysis. Cancer Cell Int. 18, 108 (2018).
Chou, S.-Y., Yen, S.-L., Huang, C.-C. & Huang, E.-Y. Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. BMC Cancer 18, 105 (2018).
Mariño, K. V., Cagnoni, A. J., Croci, D. O. & Rabinovich, G. A. Targeting galectin-driven regulatory circuits in cancer and fibrosis. Nat. Rev. Drug Discov. 22, 295–316 (2023).
Le, Q.-T. et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J. Clin. Oncol. 23, 8932–8941 (2005).
Liu, F.-T. & Rabinovich, G. A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 29–41 (2005).
Rabinovich, G. A. & Toscano, M. A. Turning ‘sweet’ on immunity: galectin–glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 9, 338–352 (2009).
Cedeno-Laurent, F. & Dimitroff, C. J. Galectin-1 research in T cell immunity: past, present and future. Clin. Immunol. 142, 107–116 (2012).
Nambiar, D. K. et al. Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. J. Clin. Investig. 129, 5553–5567 (2019).
Nambiar, D. K. et al. Galectin-1 mediates chronic STING activation in tumors to promote metastasis through MDSC recruitment. Cancer Res. 83, 3205–3219 (2023).
Mo, R., Jiang, T. & Gu, Z. Enhanced anticancer efficacy by ATP-mediated liposomal drug delivery. Angew. Chem. Int. Ed. 53, 5815–5820 (2014).
Luo, Z. et al. From aggregation-induced emission of Au(I)–thiolate complexes to ultrabright Au(0)@Au(I)–thiolate core–shell nanoclusters. J. Am. Chem. Soc. 134, 16662–16670 (2012).
Brewer, L. R., Corzett, M. & Balhorn, R. Protamine-induced condensation and decondensation of the same DNA molecule. Science 286, 120–123 (1999).
Koo, A.N. et al. Disulfide-cross-linked PEG-poly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery. Chem. Commun. (Camb.) 6570–6572 (2008).
Dutta, K., Das, R., Medeiros, J. & Thayumanavan, S. Disulfide bridging strategies in viral and nonviral platforms for nucleic acid delivery. Biochemistry 60, 966–990 (2021).
An, S. et al. Single-component self-assembled RNAi nanoparticles functionalized with tumor-targeting iNGR delivering abundant siRNA for efficient glioma therapy. Biomaterials 53, 330–340 (2015).
Lu, S. C. Dysregulation of glutathione synthesis in liver disease. Liver Res. 4, 64–73 (2020).
Ding, Y., Dai, Y., Wu, M. & Li, L. Glutathione-mediated nanomedicines for cancer diagnosis and therapy. Chem. Eng. J. 426, 128880 (2021).
Zhang, X.-D. et al. In vivo renal clearance, biodistribution, toxicity of gold nanoclusters. Biomaterials 33, 4628–4638 (2012).
Yu, J. H. et al. Highly excretable gold supraclusters for translatable in vivo raman imaging of tumors. ACS Nano 17, 2554–2567 (2023).
Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D. & Chan, W. C. W. Nanoparticle–liver interactions: cellular uptake and hepatobiliary elimination. J. Control. Release 240, 332–348 (2016).
Ookhtens, M., Hobdy, K., Corvasce, M. C., Aw, T. Y. & Kaplowitz, N. Sinusoidal efflux of glutathione in the perfused rat liver. Evidence for a carrier-mediated process. J. Clin. Investig. 75, 258–265 (1985).
Jiang, Y. & Pu, K. Molecular probes for autofluorescence-free optical imaging. Chem. Rev. 121, 13086–13131 (2021).
Jiang, Y. & Pu, K. Molecular fluorescence and photoacoustic imaging in the second near-infrared optical window using organic contrast agents. Adv. Biosyst. 2, 1700262 (2018).
Frangioni, J. V. In vivo near-infrared fluorescence imaging. Curr. Opin. Chem. Biol. 7, 626–634 (2003).
Renier, N. et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 159, 896–910 (2014).
Wang, Y. et al. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol. Ther. 21, 1919–1929 (2013).
Lei, Y. et al. Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer. Nat. Commun. 8, 15130 (2017).
Darragh, L. B. et al. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat. Cancer 3, 1300–1317 (2022).
Ito, K. et al. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis 14, 293–307 (2011).
Barabas, K., Milner, R., Lurie, D. & Adin, C. Cisplatin: a review of toxicities and therapeutic applications. Vet. Comp. Oncol. 6, 1–18 (2008).
Perše, M. Cisplatin mouse models: treatment, toxicity and translatability. Biomedicines 9, 1406 (2021).
McKibbin, T. et al. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Support. Care Cancer 24, 1789–1793 (2016).
De Felice, F. et al. Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: a systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Crit. Rev. Oncol. Hematol. 162, 103345 (2021).
de Sousa, L. G. & Ferrarotto, R. Pembrolizumab in the first-line treatment of advanced head and neck cancer. Expert Rev. Anticancer Ther. 21, 1321–1331 (2021).
Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856–1867 (2016).
Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915–1928 (2019).
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
Qiao, X.-W. et al. The evolving landscape of PD-1/PD-L1 pathway in head and neck cancer. Front. Immunol 11, 1721 (2020).
Dogan, V., Rieckmann, T., Münscher, A. & Busch, C.-J. Current studies of immunotherapy in head and neck cancer. Clin. Otolaryngol. 43, 13–21 (2018).
Tao, Y. et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann. Oncol. 34, 101–110 (2023).
Tolerance and efficacy of pembrolizumab or cetuximab combined with RT in patients with locally advanced HNSCC (PembroRad). https://clinicaltrials.gov/study/NCT02707588
Study of pembrolizumab (MK-3475) or placebo with chemoradiation in participants with locally advanced head and neck squamous cell carcinoma (MK-3475-412/KEYNOTE-412). https://clinicaltrials.gov/study/NCT03040999
Study to compare avelumab in combination with standard of care chemoradiotherapy (SoC CRT) versus SoC CRT for definitive treatment in patients with locally advanced squamous cell carcinoma of the head and neck (JAVELIN HEAD AND NECK 100). https://clinicaltrials.gov/study/NCT02952586
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111 (2017).
Daguenet, E. et al. Radiation-induced bystander and abscopal effects: important lessons from preclinical models. Br. J. Cancer 123, 339–348 (2020).
Nishiga, Y. et al. Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect. Nat. Cancer 3, 1351–1366 (2022).
Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313–322 (2018).
Brooks, E. D. & Chang, J. Y. Time to abandon single-site irradiation for inducing abscopal effects. Nat. Rev. Clin. Oncol. 16, 123–135 (2019).
Torrejon, D. Y. et al. Overcoming genetically based resistance mechanisms to PD-1 blockade. Cancer Discov. 10, 1140–1157 (2020).
Bonvalot, S. et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial. Lancet Oncol. 20, 1148–1159 (2019).
Zhang, H. et al. Gold-nanocluster-mediated delivery of siRNA to intact plant cells for efficient gene knockdown. Nano Lett. 21, 5859–5866 (2021).
Mudedla, S. K., Singam, E. R. A., Balamurugan, K. & Subramanian, V. Influence of the size and charge of gold nanoclusters on complexation with siRNA: a molecular dynamics simulation study. Phys. Chem. Chem. Phys. 17, 30307–30317 (2015).
Lee, M.-Y. et al. Target-specific gene silencing of layer-by-layer assembled gold–cysteamine/siRNA/PEI/HA nanocomplex. ACS Nano 5, 6138–6147 (2011).
Chien, C.-T. et al. Co-caged gold nanoclusters and methyl motifs lead to detoxification of dendrimers and allow cytosolic access for siRNA transfection. J. Mater. Chem. B 2, 6730–6737 (2014).
Song, C. W., Kim, M.-S., Cho, L. C., Dusenbery, K. & Sperduto, P. W. Radiobiological basis of SBRT and SRS. Int. J. Clin. Oncol. 19, 570–578 (2014).
Lynch, C., Pitroda, S. P. & Weichselbaum, R. R. Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 25, e352–e362 (2024).
Liu, S. et al. Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity. Cell Death Dis. 14, 679 (2023).
Arina, A. et al. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat. Commun. 10, 3959 (2019).
Gough, M. J. & Crittenden, M. R. The paradox of radiation and T cells in tumors. Neoplasia 31, 100808 (2022).
Dovedi, S. J. et al. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin. Cancer Res. 23, 5514–5526 (2017).
Vermorken, J. B. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116–1127 (2008).
Jonker, D. J. et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040–2048 (2007).
Boettcher, M. & McManus, M. T. Choosing the right tool for the job: RNAi, TALEN, or CRISPR. Mol. Cell 58, 575–585 (2015).
